CJC-1295
Also known as Modified GRF 1-29, CJC-1295 no DAC, CJC-1295 without DAC
Studied for: gHRH signaling
CJC-1295 without DAC, also called modified GRF 1-29, is a growth-hormone-releasing hormone analog with a short half-life, studied specifically for preserving the body's natural pulsatile release pattern.
Last reviewed September 26, 2026
How it is thought to work
Research describes it as a GHRH analog acting on pituitary receptors, with the absence of the drug affinity complex keeping its action brief rather than sustained.
- GHRH PathwayStudied as a releasing-hormone analog acting on the pituitary receptors that govern natural hormone pulses.
- Short Half-LifeWithout DAC its action is brief, which research associates with preserving the body's own pulsatile rhythm.
- Route studied
- Subcutaneous
- Receptor class
- GHRH-R
- Research status
- Early clinical
Published human data consist of small clinical studies, including a randomized controlled trial of the long-acting DAC form of CJC-1295 in healthy adults, while the no-DAC form (modified GRF 1-29) appears mainly in reviews and anti-doping detection research.
Research
What the research covers
What research examines
- Growth hormone release through GHRH receptor signaling
- Preservation of natural pulsatile growth hormone release
- GH and IGF-I secretion in healthy adults (long-acting DAC form)
- Discussion in sports medicine and orthopaedic peptide reviews
- Discussion in healthy-aging peptide reviews
- Analytical detection of GHRH analogs in anti-doping testing
Reported effects in studies
- Human safety data specific to the no-DAC form are limited
- Adverse events are not summarized in the cited titles
- Reviews discuss safety questions around unapproved peptide therapies
- GHRH synthetic analogs are targeted by anti-doping detection methods and have been identified in seized doping material
Studied range
What research protocols have used
Research protocols have used 100–300 mcg per administration, 5 days per week (pre-sleep), in 12-week blocks with 4 weeks off.
For research use only. These figures summarize published research protocols. They are not instructions or medical advice.
Every CoreX order ships with a per-lot protocol guide.
Open the reconstitution calculatorRelated compounds
Researched alongside
- GLP-3RGLP-3R is studied as a triple agonist at the GLP-1, GIP, and glucagon receptors. Research examines whether engaging all three affects metabolic regulation differently to dual or single agonists.Read profile$119
- IpamorelinIpamorelin is a selective growth-hormone secretagogue. Research examines it specifically for its selectivity, releasing growth hormone with minimal effect on cortisol or prolactin.Read profile$79
- BPC-157BPC-157 is a synthetic sequence derived from a protein found in gastric juice. Research examines its role in gut barrier integrity, connective-tissue repair, and the signaling that coordinates healing.Read profile$49
- HCGHCG is a glycoprotein hormone studied for its activity at the luteinizing hormone receptor, and for its role in research on the hypothalamic-pituitary-gonadal axis.Read profile$79
Studies
Cited research
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.
The Journal of clinical endocrinology and metabolism · 2006 · RCT · PMID 16352683
- Advances in the detection of growth hormone releasing hormone synthetic analogs.
Drug testing and analysis · 2021 · PMID 34665524
- Glycine-modified growth hormone secretagogues identified in seized doping material.
Drug testing and analysis · 2019 · PMID 30136411
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.
Sports medicine (Auckland, N.Z.) · 2026 · Review · PMID 41966639
- A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review.
The Journal of sports medicine and physical fitness · 2026 · Review · PMID 41880199
FAQ
Questions about CJC-1295
CJC-1295 without DAC, also called modified GRF 1-29, is a synthetic analog of growth-hormone-releasing hormone (GHRH). It lacks the drug affinity complex (DAC) found in the long-acting version of CJC-1295, giving it a short half-life. Research interest centers on its potential to increase the amount of growth hormone released per pulse while preserving the body's natural pulsatile release pattern, rather than producing sustained elevation.
Research describes it as a GHRH analog that acts on GHRH receptors (GHRH-R) in the pituitary, the receptors that govern natural growth hormone pulses. Because it lacks the drug affinity complex, its action is brief rather than prolonged. Research associates this short duration with preserving the body's own pulsatile rhythm of growth hormone secretion, as opposed to the continuous stimulation reported with long-acting analogs.
The DAC version is a long-acting GHRH analog. A randomized controlled trial in healthy adults reported prolonged stimulation of growth hormone and insulin-like growth factor I secretion with that form. The no-DAC form, by contrast, has a short half-life and is studied for brief, pulse-level effects. Findings from the DAC trial should not be assumed to apply directly to the no-DAC form, since their durations of action differ substantially.
Human safety data specific to CJC-1295 without DAC are limited, and adverse events are not summarized in the cited titles. Recent reviews examine the safety and efficacy of approved and unapproved peptide therapies in musculoskeletal and athletic contexts. GHRH synthetic analogs are also a focus of anti-doping research, with validated detection methods published and glycine-modified secretagogues identified in seized doping material.
Research protocols have used 100–300 mcg per administration, 5 days per week (pre-sleep), in 12-week blocks with 4 weeks off, via the subcutaneous route. These figures describe research protocols only and are not recommendations. Each CoreX order ships with a protocol guide for laboratory reference. CoreX supplies CJC-1295 without DAC for laboratory research use only.
Ask about CJC-1295
Plain answers from our library: the science, the studied ranges and our products. It can be wrong, and it does not give medical advice.
AI answers can be wrong. Research use only.
Compare
Related comparisons
- CJC-1295 vs IpamorelinCJC-1295 and Ipamorelin are both peptides studied for their effects on growth hormone release, but they act through different receptor pathways. CJC-1295 without DAC, also called modified GRF 1-29, is a growth-hormone-releasing hormone (GHRH) analog with a short half-life. Research associates its brief action with preserving natural pulsatile release. Ipamorelin is a selective growth-hormone secretagogue that acts as a ghrelin receptor agonist, studied for releasing growth hormone with minimal cortisol or prolactin response. Published human data on CJC-1295 come mainly from small clinical studies of its long-acting DAC form. Ipamorelin's primary studies are animal work on growth hormone release and bone growth. Human safety data remain limited for both.
- CJC-1295 vs SermorelinCJC-1295 and Sermorelin are both growth-hormone-releasing hormone (GHRH) analogs that act on the pituitary GHRH receptor. CJC-1295 without DAC, also called modified GRF 1-29, is described in research as a short-acting analog; lacking a drug affinity complex keeps its action brief, which research associates with preserving natural pulsatile growth hormone release. Its human evidence is early, drawn mainly from reviews, anti-doping detection work, and a small trial of the long-acting DAC form. Published reviews describe clinical use of Sermorelin in diagnosing and treating idiopathic growth hormone deficiency in children, and it continues to be discussed in research on adult-onset growth hormone insufficiency and other areas.
- Tesamorelin vs CJC-1295Tesamorelin and CJC-1295 are both growth-hormone-releasing hormone (GHRH) analogs studied for their action on pituitary GHRH receptors. Tesamorelin is described in research as a modified GHRH analog engineered for greater stability than the native hormone, and published reviews describe human clinical research on it, particularly on visceral adipose tissue in HIV-associated lipodystrophy. CJC-1295 without DAC, also called modified GRF 1-29, is characterized by a short half-life; without the drug affinity complex its action is brief, which research associates with preserving natural pulsatile growth hormone release. Human data for the no-DAC form are limited, appearing mainly in reviews and anti-doping detection research, while a small randomized trial studied the long-acting DAC form in healthy adults.